Background: Despite primary prophylaxis of febrile neutropenia (FN) with pegfilgrastim, studies have demonstrated a significant number of breakthrough FN events among Asian lymphoma patients receiving chemotherapy. This study was designed to investigate the association of pegfilgrastim concentrations during the lowest point of absolute neutrophil count (ANC nadir) after chemotherapy administration and the occurrence of breakthrough FN, to evaluate whether Therapeutic drug monitoring of pegfilgrastim can guide management of FN.
INTRODUCTION
Febrile neutropenia (FN) is a major dose-limiting toxicity of chemotherapy which often requires prolonged hospitalization and use of broadspectrum antibiotics 1 . It can lead to dose reductions or treatment delays in subsequent chemotherapy cycles and therefore compromise cancer treatment outcomes. Studies have shown that appropriate prophylactic usage of granulocyte colonystimulating factors (G-CSFs) can reduce the risk, severity and duration of FN 1 . Currently, international guidelines such as the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) recommend routine primary prophylaxis with G-CSFs for the prevention of FN in patients receiving high-risk chemotherapy regimens that are associated with 20% and above incidence for FN. Use of G-CSFs for primary prophylaxis is also supported in patients who are at intermediate risk of FN, including patients who are above 65 years, pre-existing neutropenia and poor performance status 2, 3 .
Pegfilgrastim is a pegylated form of the recombinant human G-CSF, filgrastim, which includes a 20 kD polyethylene glycol (PEG) molecule covalently attached to the N-terminal methionine residue of filgrastim 4, 5 . This addition lengthens the half-life Proceedings of Singapore Healthcare  Volume 23  Number 1  2014 and duration of action, which allows pegfilgrastim to be given as a single dose of 6 mg per cycle of chemotherapy for FN prophylaxis 6 . Neutrophilmediated clearance is the primary mechanism of clearance for pegfilgrastim, as shown in bilaterally nephrectomized rats whereby the molecular size of pegfilgrastim exceeded the threshold for glomerular filtration 7 . A study modeling the pharmacokinetics and pharmacodynamics of pegfilgrastim in healthy subjects predicted that the lowest concentration required for meaningful granulopoiesis should be at least 2 ng/ml 4 . Similarly, another correlation study concluded that subtherapeutic pegfilgrastim concentrations (less than 2 ng/ml) were predicted only after postnadir absolute neutrophil count (ANC) recovery to 1 x 10 9 /L or greater, again reflecting neutrophil-mediated clearance as the predominant elimination pathway 8 . These studies suggested that one dose of 6 mg should sustain adequate pegfilgrastim concentrations to stimulate granulopoiesis in a patient. As a result, the NCCN guideline on the use of myeloid growth factors does not recommend the administration of additional filgrastim in FN patients who have already received prophylactic pegfilgrastim, based on published pharmacokinetic data suggesting a lack of benefit [3] [4] 8 .
At National Cancer Centre Singapore (NCCS), pegfilgrastim is routinely administered in lymphoma patients after completion of myelosuppressive chemotherapy as primary prophylaxis against FN. This is because lymphoma chemotherapy regimens are often highly myelosuppressive and predispose patients to an increased risk of developing FN. For example, CHOP chemotherapy, (a combination of cyclophosphamide, doxorubicin, vincristine and prednisolone) which is commonly used in the treatment of non-Hodgkin's lymphoma (NHL) is associated with an absolute risk of FN of 17-50% in patients who do not receive routine G-CSF prophylaxis 9 . However, despite primary prophylaxis with pegfilgrastim, risk of FN is reduced but some patients may still be at risk for developing FN. Two local studies demonstrated that the incidence of breakthrough FN in Asian lymphoma patients remained high, ranging from 13-16%, despite receiving adequate prophylaxis with pegfilgrastim 10, 11 .
To date, there is a lack of research evaluating the role of monitoring pegfilgrastim concentrations, as therapeutic drug monitoring (TDM) of pegfilgrastim concentrations is not routinely performed in clinical practice. With local studies also showing higher FN rates in Asians compared to Caucasian patients receiving the same type of chemotherapy, it may suggest that Asian patients possess other factors that elevate one's risk for FN 12, 13 . With regards to pegfilgrastim, we question the possibility of Asian patients having a faster clearance of the drug.
Through monitoring of post-chemotherapy pegfilgrastim drug concentrations during the period of ANC nadir and breakthrough FN, we hope to find out if the results from our local patient population agree with published pharmacokinetic and pharmacodynamic studies, which demonstrated that pegfilgrastim concentrations remained above therapeutic level during the period of chemotherapy-induced neutropenia, and its concentration sustained until onset of ANC recovery (to 1 x 10 9 /L or greater). If pegfilgrastim concentrations remain therapeutic, this would support the current recommendations that supplementation of once-daily filgrastim for the treatment of breakthrough FN after pegfilgrastim prophylaxis is not necessary 3 . However, if concentrations are found to be subtherapeutic, it would be prudent to identify characteristics that may predispose these patients to higher risk for FN, so that treatment of breakthrough FN with filgrastim would be justified in these patients. Hence, the primary objective of this study is to investigate the association of pegfilgrastim drug concentrations during the period of ANC nadir after chemotherapy administration and occurrence of breakthrough FN, to evaluate whether TDM can guide the appropriate usage of filgrastim in the treatment of FN
METHODS

Study Design and Setting
This was a single-centre, observational, prospective cohort study conducted at National Cancer Centre Singapore (NCCS). This study was approved by the SingHealth Centralized Institutional Review Board. Patient informed consent was obtained for all patients enrolled into the study.
Patients
Lymphoma patients who received prophylactic pegfilgrastim after completion of their chemotherapy were eligible for this study. Patients who were unable to give informed consent, those below 21 years old, pregnant Proceedings of Singapore Healthcare  Volume 23  Number 1  2014 women and prisoners were excluded. At NCCS, pegfilgrastim is administered 24-72 hours after chemotherapy, which is in accordance to the current recommendations in the package insert.
Procedures
Data collection
A data collection form was created and the following patient-related information were collected at the time of enrollment: patient demographics (age at the time of consent, gender, height and weight), disease characteristics (primary diagnosis, clinical stage, co-morbidities), current chemotherapy (chemotherapy regimen, relative dose intensity, cycle number, and concurrent antimicrobial prophylaxis), baseline pre-chemotherapy complete blood counts (CBC), other medication history (dose and administration) and history of previous episodes of FN
Blood draws
For each patient, a blood sample (5 ml) was drawn before pegfilgrastim administration. This blood draw was performed to measure the baseline endogenous G-CSF concentration before pegfilgrastim administration. A second blood sample (5 ml) was taken during the ANC nadir check after each chemotherapy cycle. The day of ANC nadir check was determined at the oncologists' discretion, ranging from Day 7 to Day 12 after chemotherapy. If a patient developed breakthrough FN, a blood sample (5 ml) was also taken to measure total G-CSF concentrations on the day of or after development of FN, but before being given supplemental doses of once-daily filgrastim during that admission for treatment of breakthrough FN.
Follow up laboratory results
Complete blood count results analyzed by the hospital laboratory were recorded during the ANC nadir check, and during each episode of breakthrough FN. Additional results taken during breakthrough FN included: vital signs, renal and liver function tests, radiologic results, microorganism culture results (if any) and including those for calculation of the Multinational Association for Supportive Care in Cancer (MASCC) score 14 .
Pegfilgrastim blood samples processing
Patients' blood samples were collected in serum separator tubes (SST), allowed to clot for 30 minutes, and centrifuged for 15 minutes at 1000× g to separate out the serum component. Each serum sample was then extracted and divided into two aliquots, and stored in cryotubes at -80°C. The serum samples were finally assayed with two replicates per sample aliquot, using an enzyme-linked immunosorbent assay (ELISA) test (manufactured by GenWay®). The test kit can detect a range between 0.0312 ng/ml to 2 ng/ml, with a sensitivity of less than 0.004 ng/ml. Total G-CSF concentrations were measured, which included G-CSF of both endogenous and exogenous origin (including pegfilgrastim), as the assay does not differentiate between the two. The optical density (O.D.) absorbance at a wavelength of 450 nm was read using a Tecan M200 Pro microplate reader.
Definitions
In this study, FN was defined as a single temperature of greater than 38.3°C or a temperature of greater than 38°C for more than one hour, in the presence of severe neutropenia (absolute neutrophil count <0.5 x 109/L) 3. Breakthrough FN was defined as FN occurring despite pegfilgrastim prophylaxis 11 . Pegfilgrastim serum concentrations were calculated by subtracting the baseline endogenous G-CSF concentrations (obtained before pegfilgrastim administration post-chemotherapy) from the total G-CSF concentrations (obtained after pegfilgrastim administration at specific study time points detailed under Procedures) 4 . Day 1 of chemotherapy referred to the day patient received the most immunosuppressive agent in their chemotherapy regimen. The ANC nadir was the lowest value of ANC post-chemotherapy, and the day of ANC nadir was determined at oncologist's discretion. The Multinational Association for Supportive Care in Cancer (MASCC) score is a validated risk index which identifies patients at low risk for complications and may be used to select patients suitable for outpatient treatment of FN 14 . A score of 21 or greater (out of a maximum of 26) identifies low risk patients.
Endpoints
The primary objectives of this study were to investigate the proportion of patients possessing subtherapeutic pegfilgrastim concentrations (less than 2 ng/ml) at the point of nadir after chemotherapy, and also the association of pegfilgrastim drug concentrations during neutropenic period with the occurrence of breakthrough FN in lymphoma patients postchemotherapy. The secondary objective was to Proceedings of Singapore Healthcare  Volume 23  Number 1  2014 identify the possible risk factors in lymphoma patients with breakthrough FN.
Statistical analysis
Descriptive statistics were used to summarize patient demographics and baseline clinical characteristics. For primary endpoints, the proportion of patients with subtherapeutic pegfilgrastim concentrations at ANC nadir was summarized with descriptive statistics.
Comparisons of pegfilgrastim concentrations and ANC levels between the two groups (patients who develop breakthrough FN versus those who do not) were performed using independent samples t-test or Mann-Whitney U test as appropriate, while correlation curves were drawn to illustrate the relationship between pegfilgrastim concentrations and ANC levels. The mean MASCC score for the group who developed breakthrough FN was calculated as well. All data analyses were performed with SPSS version 19 and Microsoft Excel 2010.
RESULTS
Demographics
A total of 19 patients were enrolled into the study from May to August 2012. Five patients declined to participate. Fourteen patients received one cycle of pegfilgrastim and 5 patients received two cycles of pegfilgrastim. Pegfilgrastim was administered in 23 cycles of chemotherapy. In the second cycle, two patients withdrew from the study as they were not willing to return for ANC nadir blood draw. Therefore, baseline pegfilgrastim blood samples were obtained for a total of 24 chemotherapy cycles, while pegfilgrastim blood samples at ANC nadir were obtained for 21 chemotherapy cycles during the course of the study ( Table 1) .
Association of pegfilgrastim concentrations and occurrence of FN at ANC nadir
Nineteen patients with 21 completed pegfilgrastim cycles had a median G-CSF concentration of 0.063 (range 0.037-0.102) ng/ml at baseline, which reflected their endogenous G-CSF concentrations before pegfilgrastim administration. The estimated timing of ANC nadir was Day 10 (range Day 7-12) post-chemotherapy. The median pegfilgrastim concentration at the ANC nadir was 0.297 (range 0.001-0.828) ng/ml. The median ANC levels during the period of ANC nadir was 5.66 (range 0.00-22.36)×10 9 /L. A total of three (15.8%) patients developed breakthrough FN. Among patients who developed breakthrough FN, the median pegfilgrastim concentration was 0.257 (range 0.231-0.631) ng/ ml, compared to patients who did not develop FN, who had a median pegfilgrastim concentration of 0.299 (range 0.001-0.829) ng/ml. This difference was not statistically significant (p=0.740). The median ANC nadir was 1.68 (range 0.00-1.73)×10 9 / L in patients who developed breakthrough FN, while those who did not had a median ANC nadir of 6.30 (range 0.00-22.36)×10 9 /L. This difference was statistically significant (p=0.017). There was a trend of decreasing pegfilgrastim concentrations as ANC levels increased ( Fig. 1 , correlation coefficient −0.395; p=0.104).
A similar trend of lower pegfilgrastim concentrations was seen during ANC nadir in patients with higher baseline ANC levels (Fig. 2 , correlation coefficient −0.091; p=0.695), and higher baseline creatinine clearance values (Fig. 3 , correlation coefficient −0.134; p = 0.563), but these were not statistically significant as well.
Three (15.8%) out of 19 patients had ANC levels less than 1×10 9 /L (two subjects had undetectable levels of ANC; one patient had an ANC level 0.49×10 9 /L), and pegfilgrastim concentrations less than 2 ng/ml. One out of these three patients developed breakthrough FN. Table 2 shows the individual pegfilgrastim concentrations of these three patients during the ANC nadir, the ANC nadir (×10 9 /L) Pegfilgrastim (ng/ml) Fig. 1 . Relationship between pegfilgrastim concentrations (ng/ ml) and ANC levels (×10 9 /L) during period of ANC nadir postchemotherapy Table 3 shows the individual patient characteristics, pegfilgrastim concentrations during the ANC nadir, the corresponding ANC levels, MASCC scores and the chemotherapy treatment administered. On the day of diagnosis of breakthrough FN, ANC levels were not detectable in all three patients. The MASCC risk index scores for these three patients were 16, 24 and 21, respectively, with a mean score of 20.3 (±SD 4.04). Only one patient scored lower than 21. All three patients were not chemo-naïve and did not have any prior history of FN.
Patient and chemotherapy regimen-related risk factors for FN between the two groups
Analyses performed on the following variables: age, gender, race, ECOG status, chemotherapy 
DISCUSSION
This study did not show any difference in pegfilgrastim levels during the ANC nadir between the patients who developed breakthrough FN and those who did not. All patients had subtherapeutic Abbreviations: Chemotx regimen, chemotherapy regimen; ANC_B, ANC at baseline; ANC_N, ANC at nadir; ND: Not detected; Peg, pegfilgrastim; RDI, relative dose intensity. to patients who did not develop breakthrough FN. The NCCN guidelines had listed pre-existing neutropenia as a risk factor for breakthrough FN4. Although the baseline ANC levels in these patients were not in the neutropenic range, a lower baseline predisposes patients to more profound neutropenia after myelosuppressive lymphoma chemotherapy regimens, and may increase their risk of developing breakthrough FN. This trend was observed in all three patients who developed breakthrough FN as they had non-detectable ANC levels on the day breakthrough FN occurred.
There were a number of limitations in this pilot study. As the study was performed in a small sample size of patients within a short study time frame, this limited the number of patients manifesting breakthrough FN, although the breakthrough FN rate of 16% in this study corresponded to those reported in previous studies done locally 10, 11 . Having more patients with breakthrough FN and consequently more breakthrough FN blood samples would improve the investigation of the relationship of pegfilgrastim concentrations in comparison to the patients who did not develop breakthrough FN. Another limitation was that the timing of ANC nadir blood draw was determined by the primary oncologist, and done mostly on Day 10, in accordance to literature which reports that ANC nadir usually occurs between Days 10 to 14 15 . However, because the study included all lymphoma patients who were treated with different chemotherapy regimens and at different relative dose intensities, the actual day of ANC nadir could have been potentially affected. It was possible that this may have led to overestimation of the timing for ANC nadir in most of the study patients and resulted in subtherapeutic pegfilgrastim concentrations post ANC recovery. Similarly, among the three patients who developed breakthrough FN, blood sampling was performed on the same day for one of them while samples from the other two patients were obtained the day after development of breakthrough FN. The ANC levels in these two patients had gone past ANC nadir to levels above 1×10 9 /L by then, providing an explanation for their subtherapeutic pegfilgrastim levels and indicating that samples drawn on the same day as breakthrough FN is more ideal. Additionally, although steps were taken to minimize laboratory and sample processing error by performing the ELISA assay with sample replicates, this probability could not be ruled out pegfilgrastim concentrations because a majority of the patients had ANC levels above 1×10 9 /L by Day 10 post-chemotherapy, indicating that they had likely recovered from their post-chemotherapy ANC nadir. This trend was in agreement with published pharmacokinetic data 9, 13 . In addition, statistically significant difference was not detected with age, gender, race, ECOG status, chemotherapy cycle, current chemotherapy intensity, and baseline creatinine clearance between the two groups of patients.
Correlation analyses demonstrated a nonsignificant trend of decreasing pegfilgrastim concentrations with increasing ANC levels, alluding to its neutrophil-mediated mechanism of clearance, with renal clearance being an additional minor pathway of drug elimination. Similar trends of lower pegfilgrastim concentrations during the ANC nadir were also seen in patients with higher baseline ANC levels and higher creatinine clearance values at baseline pre-chemotherapy, although they were not found to be statistically significant. However, for the remaining three patients with low ANC levels, the reason for their corresponding subtherapeutic pegfilgrastim concentrations remained unclear.
Studies have illustrated that the development of breakthrough FN is multi-factorial and involves both patient-and chemotherapy-related factors, and may not be primarily determined by G-CSF concentrations [9] [10] [11] [12] [13] .Of note, only one out of these three patients developed breakthrough FN. Routine co-administration of prophylactic antimicrobials in this study population may have conferred some protection against development of FN.
Among the three patients who developed FN, only one patient had a low MASCC risk index score of 16, indicative of being at high risk of FN complications. However, all three patients were treated as inpatients as per institutional practices. The reason for the more conservative management of breakthrough FN in Asian patients may be because of the higher risk of FN seen in this population while receiving the same chemotherapy as their international counterparts, as reflected in local studies 12, 13 . Thus, oncologists may opt to be more cautious due to the possibility that Asians may be more susceptible to complications of FN.
In this study, patients who developed breakthrough FN had lower baseline white blood cell counts and similarly lower baseline ANC levels compared Proceedings of Singapore Healthcare  Volume 23  Number 1  2014 as only one blood sample per patient per time point was obtained, and the ELISA assay performed only once. It should be acknowledged that the ELISA assay should preferably be repeated, each time with at least two blood samples per time point, taken serially before and after pegfilgrastim administration, past the ANC nadir and until ANC recovery, to better monitor for the change in pegfilgrastim concentrations with ANC levels and strengthen the study hypothesis. However, this would possibly affect patient recruitment for enrolment in the study in the local setting.
CONCLUSION
This pilot study has demonstrated that there was no difference in pegfilgrastim levels during ANC nadir between patients who developed breakthrough FN and those who did not. With limited data available, routine therapeutic drug monitoring of pegfilgrastim concentrations cannot be recommended at this point in time for patients receiving pegfilgrastim post-chemotherapy for FN prophylaxis. The identification of patients with subtherapeutic pegfilgrastim concentrations during breakthrough FN episode and yet have low ANC levels warrants further investigation. A study design that incorporates serial blood sampling before and after pegfilgrastim drug administration, and past ANC recovery, would allow the investigation of whether subtherapeutic pegfilgrastim concentrations exist during breakthrough FN.
